Avelox is a fluoroquinolone antibacterial drug with a bactericidal action.
Release form and composition
Aveloks produced in the form of tablets, coated tablets and solution for infusion. The active substance - moxifloxacin. Excipients:
- Lactose monohydrate;
- Croscarmellose sodium;
- Magnesium stearate;
- Iron oxide yellow;
- Macrogol 4000;
- Titanium Dioxide.
Moxifloxacin, causing profound structural changes in the cell wall of the pathogen, causes the death of the pathogenic agent. The release of toxic components in the destruction of the pathogen minimum, which reduces the risk of severe toxicity during use Avelox.
Avelox is indicated for:
- Infectious processes of the lungs and ENT;
- Intra-abdominal and urogenital infections;
- Infectious diseases of the soft tissues and skin.
Activity Aveloks manifested in a broad spectrum of gram-positive and gram-negative microorganisms, bacteria resistant to beta-lactam antibiotics and macrolide, and atypical acid-fast bacteria forms of microorganisms and anaerobic bacteria resistant to drug resistance.
The instructions to aveloks stated that its application is inadmissible in such diseases as pseudomembranous colitis and severe renal insufficiency. Prohibited pills to pregnant and lactating women, children under 18 and people with individual intolerance to any ingredient of the product. Particular caution is required when prescribing medicines for patients with diseases of the central nervous system, suggesting the likelihood of seizures. Diseases such as liver failure, acute myocardial ischemia, bradycardia, hypokalemia are also reason for caution in the appointment of Avelox.
Dosage and Administration
Admission Avelox can be carried out at any time, regardless of the meal. Swallow whole tablets, as the integrity of their shell can not be broken. The half-life of the drug - a lengthy process, so the drug is enough to take once a day. The daily therapeutic dose should not exceed 400 mg. After oral Avelox is absorbed quickly and almost completely. The maximum level of the drug in the blood after a single use is observed after 0, 5-4 hours after ingestion. Achieving a stable level of moxifloxacin in plasma occurs after three days of regular intake.
Infusion therapy is carried out either at the start of treatment with subsequent transfer of the patient to the use of Avelox tablets or used until recovery.
Depending on the disease duration of therapy is 7 to 10 days.
According to reviews, side effects occur infrequently, under normal dosing. The instructions to Avelox contain the following possible negative consequences:
- Nausea, vomiting, abdominal pain, taste disturbance, stomatitis, diarrhea;
- Increased heart rate, chest pain, palpitations, high blood pressure;
- Dizziness, sleep disturbance, feelings of depression, anxiety, confusion, weakness;
- Back pain, pain in muscles and joints, tenosynovitis, tendon rupture;
- Itching, skin rash;
- Hyperglycemia, hyperlipidemia, hyperuricemia;
- Malaise, edema.
When the pain in the joints or tendons when receiving Aveloks drug overturned to prevent rupture of the tendon.
In patients with epilepsy Avelox may provoke seizures.
With the development of severe diarrhea while taking Avelox, it overturned.
Antacids and enterosorbents and drugs, which include iron, aluminum and magnesium should occur at different times with Avelox, the difference must be at least 4 hours.
The drug is not used to treat children.
Avelox analogues of the active substance are the following drugs: Vigamoks; Moksimak; Moksin; Moxifloxacin; Moxifloxacin hydrochloride; Pleviloks. By the same pharmacological subgroup include Abaktal; Basij; Gatispan; Dzheofloks; Zanotsin; Ksenakvin; Levofloks; Normaks; Ofloxacin; Ciprofloxacin, and others.
Terms and conditions of storage
Avelox should be stored in a dry, dark place at a temperature no higher than 25 ° C. Keep away from children. Shelf life of the solution - 3 years, tablets - 5 years.